New hope for rare bleeding disorder: drug shows promise in small trial
NCT ID NCT07136857
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests an investigational drug called eptacog beta for people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Over 9 months, 6 participants will use the drug to treat serious bleeding episodes, and some may choose an extra 6-month phase to prevent bleeding with regular infusions. The goal is to see if the drug safely controls bleeding without needing lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arthur M. Blank Hospital | Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30329, United States
Conditions
Explore the condition pages connected to this study.